Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

12/06/2025 Eastern Time in USA, the Dow Jones Industrial Average(DJI.US) rose by 0.24%, closing at 42967.62 points; the NASDAQ(IXIC.US) rose by 0.24%, closing at 19662.48 points; the S&P 500 index(SPX.US) rose by 0.38%, closing at 6045.26 points. 

Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Liminatus Pharma Inc. Ordinary Shares: Overnight gain 82.8%, Regains Nasdaq compliance, improves governance, and attracts investors with innovative cancer therapy research.

Liminatus Pharma, Inc. (NASDAQ: LMNL), a Delaware-based preclinical biopharmaceutical company founded on November 23, 2022, is at the forefront of developing novel immunomodulatory cancer therapies. The company's lead candidate, IBA101, is a humanized anti-CD47 monoclonal antibody, positioning Liminatus as a potential key player in the oncology space. The firm is strategically focused on advancing next-generation CD47 checkpoint inhibitors for patients with advanced solid tumors, including non-small cell lung cancer (NSCLC). This approach aligns with the growing trend of targeted immunotherapies in oncology treatment paradigms. Liminatus Pharma aims to establish itself as a global leader in the biopharmaceutical industry by developing a pipeline of transformative therapies for cancer patients. The company's innovative approach and focus on unmet medical needs in oncology could potentially disrupt current treatment landscapes and offer new hope for patients with difficult-to-treat cancers. As Liminatus progresses its pipeline and moves closer to clinical trials, investors and industry observers will be closely monitoring the company's developments, particularly the advancement of IBA101 and its potential impact on the competitive landscape of cancer immunotherapies.

Liminatus Pharma Inc. Ordinary Shares(LIMN.US) experienced a significant surge in stock price due to multiple factors. The company's announcement of regaining compliance with Nasdaq listing requirements resolved previous issues stemming from delayed 10-Q filings, bolstering investor confidence. The timely submission of the 10-Q on June 2nd demonstrated Liminatus Pharma's commitment to improving corporate governance and transparency. Furthermore, as a biopharmaceutical company focused on developing innovative immunomodulatory cancer therapies, LIMN's research direction has attracted investor attention. These factors collectively drove the stock's substantial appreciation, resulting in an overnight gain of 82.8% and a year-to-date increase of 215.9%. The company's efforts to address compliance concerns and its promising research focus have contributed to renewed investor interest in Liminatus Pharma Inc. Ordinary Shares (LIMN).

UroGen Pharma Ltd.: Overnight gain 51.8%, Surges on pipeline breakthrough, positive trial results, and potential strategic partnerships

UroGen Pharma Ltd. (NASDAQ: URGN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for urological diseases. The company was founded in April 2004 under the name TheraCoat Ltd. and was incorporated under the laws of Israel. In September 2015, the company rebranded to its current name. UroGen's core business is centered on the development of novel treatment modalities aimed at revolutionizing the standard of care in uro-oncology and urology. The company's pipeline leverages its proprietary RTGel™ technology platform to improve the efficacy and durability of treatments for various urological conditions. With a mission to transform the landscape of urological patient care, UroGen is dedicated to addressing significant unmet medical needs in this therapeutic area. The company's innovative approach seeks to enhance treatment outcomes and potentially reduce the burden of care for patients suffering from urological disorders. As UroGen Pharma continues to advance its clinical programs, investors and industry observers are closely monitoring the company's progress in bringing its pioneering therapies to market, which could potentially disrupt the current treatment paradigms in urology and uro-oncology.

UroGen Pharma Ltd.(URGN.US), a clinical-stage biopharmaceutical company focused on urological disease treatments, experienced a significant 51.8% single-day stock price surge. This remarkable uptick can be attributed to several factors, including potential breakthroughs in its research pipeline or positive clinical trial results. The substantial gain reflects market optimism about the company's prospects, possibly fueled by rumors of strategic partnerships or acquisition interest. Additionally, the overall positive trend in the biotech sector has contributed to URGN's stock price appreciation. With a current market capitalization of $511 million, UroGen Pharma's valuation underscores investor confidence in its innovative capabilities within the urological disease space. This notable performance highlights the company's potential to deliver value in a competitive pharmaceutical landscape.

DeFi Development Corp. Ordinary Shares: Overnight gain 20.1%, Funding agreement, partnerships, management changes, and blockchain involvement drive stock surge

DeFi Development, a Delaware-based company founded in 2018, is a leading innovator in the commercial real estate fintech sector. The firm operates a cutting-edge B2B platform designed to streamline and enhance the efficiency and transparency of commercial property lending transactions. Leveraging advanced technological solutions, DeFi Development Corp. aims to democratize the commercial real estate loan market, facilitating broader market participation and driving industry-wide transformation. The company's proprietary platform serves as a nexus for borrowers and lenders, offering a seamless interface for deal origination, underwriting, and execution. Since its inception, DeFi Development Corp. has been at the forefront of disrupting traditional commercial real estate financing models. The company's mission is to create a more open and inclusive ecosystem for commercial property financing, potentially unlocking new opportunities for a diverse range of market participants. By harnessing the power of financial technology, DeFi Development Corp. is poised to address long-standing inefficiencies in the commercial real estate lending space, potentially reducing transaction costs and accelerating deal flow. As the company continues to expand its footprint, it remains committed to fostering innovation and driving positive change across the commercial real estate finance landscape.

DeFi Development Corp. Ordinary Shares(DFDV.US) has experienced a significant surge in stock price, driven by multiple factors. The company secured a $5 billion equity credit line agreement with RK Capital Management LLC, bolstering its financial position for future growth. Additionally, DFDV announced a strategic partnership with Drift Protocol, expanding its footprint in the decentralized finance sector. The appointment of a new Executive Vice President of Finance has strengthened the management team. DFDV has also actively engaged in the Solana ecosystem, holding and staking SOL while operating validator infrastructure. Furthermore, the company announced a 7-for-1 stock split, potentially enhancing liquidity. These positive developments collectively propelled DFDV's stock price up by 20.1%, contributing to an impressive year-to-date gain of 4,450.2%.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team.